Part 8/13:
The Center for Drug Evaluation (CDE) under the NMPA briefly suspended access to approval data earlier in the year, citing editorial mistakes. Nevertheless, discrepancies re-emerged following the resumption of public access to information.
Legal complexities add further layers to the concerns surrounding drug regulation. Some generic drug approvals have shown identical key data which experts categorize as "virtually impossible," raising alarms about potential alterations to submissions without requisite updates.
This ongoing controversy goes beyond individual regulatory failures; it speaks to a systemic issue regarding drug oversight in China and highlights an urgent need for comprehensive reforms to ensure integrity and public safety in healthcare provisions.